Intrarenal Aminopeptidase N Inhibition Augments Natriuretic Responses to Angiotensin III in Angiotensin
Type 1 Receptor-Blocked Rats T he renin-angiotensin system (RAS) is a coordinated hormonal cascade that governs fluid and electrolyte balance and blood pressure (BP). In recent years, a major emphasis has been placed on distinguishing the roles of the systemic circulating RAS from local tissue RAS. Studies have demonstrated the importance of a tissue RAS in the brain, peripheral blood vessels, adrenal glands, and kidneys. [1] [2] [3] [4] [5] [6] [7] An essential requirement for a tissue RAS is that all of the components necessary for the biosynthesis of active peptide products reside within the tissue. In the kidney, renin, angiotensinogen, and angiotensin-converting enzyme mRNA have been localized in a site-specific manner. 8 -11 Renal interstitial (RI) fluid has been shown to contain nanomolar levels of angiotensin II (Ang II) and des-aspartyl 1 -Ang II (Ang III), which are Ϸ1000-fold higher than in the plasma. 12 These observations, together with the findings that the angiotensin type 1 (AT 1 ) and angiotensin type 2 (AT 2 ) receptors have been found in glomerular epithelial cells, cortical tubules, and interstitial cells, [13] [14] [15] have resulted in attempts to define the distinctive roles of the intrarenal RAS.
Although Ang II has been considered the major effector peptide of the RAS, Ang III also demonstrates biologic activity. Ang II is converted to Ang III by aminopeptidase A, which is further converted to des-arginine 2 -Ang III (Ang IV) by aminopeptidase N ([APN] Figure 1 ). Some actions originally attributed to Ang II in the brain, such as vasopressin release, have now been found to be attributable to Ang III. 16 In the kidney, RI administration of Ang III, but not Ang II, engenders natriuresis in AT 1 receptor-blocked rats. 17 In addition, Ang III-induced natriuresis seems to be mediated by the AT 2 receptor, because the natriuretic response is abolished by the addition of PD-123319 (PD), a specific AT 2 receptor antagonist. 17 The metabolism of Ang III to Ang IV is mediated by APN, a homodimeric, membrane-bound, zinc-dependent aminopep-tidase that preferentially releases neutral amino acids from the N-terminal end of oligopeptides. 18, 19 A specific APN inhibitor (inhibition constant [K i ]ϭ8.0Ϯ1.7 nM), 2-amino-4-methylsulfonyl-butane-thiol ([PC-18] Figure 1 ), has been shown to increase the half-life of endogenous Ang III in vivo. 20 In the present study, we evaluated the renal sodium (Na ϩ ) excretion rate (U Na V) in response to selective intrarenal infusion of Ang III with and without PC-18, in the presence of candesartan (CAND), an insurmountable nonpeptide AT 1 receptor antagonist. In addition, we evaluated the natriuretic response to Ang III plus PC-18 in the presence of PD to confirm the role of the AT 2 receptor in natriuresis.
Methods

Animal Preparation
The experiments, which were approved by the University of Virginia Animal Research Committee, were conducted in 250-g SpragueDawley rats (Harlan, Teklad; Nϭ21 total). All of the studies were conducted in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals. Rats were placed under general anesthesia with pentobarbital (50 mg/mL) given 5 mg/100 g body weight IP, which resulted in deep anesthesia for control (60 minutes) and 3 (30 minutes each) experimental periods. A tracheostomy was performed in all of the rats, and arterial access was achieved by direct cannulation of the right carotid artery. Intravenous access was obtained via cannulation of the right internal jugular vein in each rat. Rats were housed under controlled conditions (temperature: 21Ϯ1°C; humidity: 60Ϯ10%; and light: 8 to 20 hours). Experiments were initiated at the same time each day to prevent any diurnal variation in BP.
Renal Cortical Interstitial Infusion
Through a midline laparotomy, the right and left kidneys were exposed. A polyethylene interstitial infusion tube was inserted inside a 15-cm long PE-60 tube, and a gauze mesh was glued to the junction. Through a 30-gauge needle, the PE-10 tube was inserted into the kidney at 0.2 cm to access the cortical interstitial space. To prevent dislodging, the gauze mesh was glued to the surface of the kidney using Vetabond glue (3 mol/L Animal Care Products). The infusion catheters were connected to a Harvard pump 5522, and substances were infused directly into the renal cortical interstitial compartment. When dual substances were infused, they were combined immediately before the experimental periods.
BP Measurements
Mean arterial BP (MAP) was measured by the direct intracarotid method with the use of a BP analyzer (Micromed Inc). MAPs were recorded every 5 minutes and averaged for each of the control and experimental periods.
Effects of Unilateral RI Ang III and Systemic AT 1 Receptor Blockade on U Na V in Rats on Normal Na ؉ Intake
Rats (Nϭ8 per group) were studied on normal Na ϩ intake, with both kidneys intact. Using a sterile technique, osmotic micropumps (Alzet 8.0 L/h per day) were implanted into the interscapular region with the animals under short-term anesthesia with ketamine (100 mg/mL) and xylazine (20 mg/mL) for CAND (0.01 mg/kg per minute) infusion 24 hours before and during the experiment. The right kidney was infused with 5% dextrose in water (2.5 L/min) vehicle directly into the RI space during both control (1 hour) and experimental collection periods (30 minutes each) and served as the control kidney. Ang III (3.5, 7, 14, and 28 nmol/kg per minute) was infused cumulatively into the RI space of the left (experimental) kidney after a 1-hour control infusion of vehicle. Both ureters were cannulated individually to collect urine for quantification of U Na V for the control and 4 experimental periods from both the right (control) and left (experimental) kidneys.
Effects of Unilateral RI Ang III Plus PC-18 on U Na V in Rats on Normal Na ؉ Intake in the Presence of Systemic AT 1 Receptor Blockade Rats (Nϭ7) were studied on normal Na ϩ intake with both kidneys intact. Using a sterile technique, osmotic micropumps were implanted into the interscapular region with the animals under shortterm anesthesia with ketamine (100 mg/mL) and xylazine (20 mg/mL) for CAND (0.01 mg/kg per minute) infusion 24 hours before and during the experiment. The right kidney was infused with vehicle directly into the RI space during both control (1 hour) and experimental collection periods (30 minutes each) and served as the control kidney. Ang III (3.5, 7, 14, and 28 nmol/kg per minute) plus PC-18 (25 g/min) was infused cumulatively into the RI space of the left (experimental) kidney after a 1-hour control infusion of 5% dextrose in water (2.5 L/min). Both ureters were cannulated individually to collect urine for quantification of U Na V for the control (1 hour) and 4 experimental (30 minutes each) periods from both the right (control) and left (experimental) kidneys.
Effects of RI Ang III Plus PC-18 Combined With PD in the Presence of Systemic AT 1 R Blockade
Rats (Nϭ6) were studied on normal Na ϩ intake with both kidneys intact. Osmotic micropumps were implanted into the interscapular region with the animals under short-term anesthesia with ketamine (100 mg/mL) and xylazine (20 mg/mL) for CAND (0.01 mg/kg per minute) infusion 24 hours before and during the experiment. Ang III (3.5, 7, 14, and 28 nmol/kg per minute) plus PC-18 (25 g/min) plus PD (10 g/kg per minute) were infused cumulatively into the RI space of the left kidney after a 1-hour control infusion of vehicle. The right kidney was infused with vehicle directly into the RI space during both control (1 hour) and experimental collection periods (30 minutes each) and served as the control kidney. Both ureters were cannulated individually to collect urine for quantification of U Na V for the control (1 hour) and 4 experimental (30 minutes each) periods from both the right and left kidneys.
Pharmacological Agents
Ang III ([des-Asp 1 ]-Ang II; Bachem), an AT 1 and AT 2 receptor agonist, was used for these studies (K i 10.5ϫ10 Ϫ9 mol/L and 2.2ϫ10 Ϫ9 mol/L for AT 1 and AT 2 receptors, respectively, in the brain 21 ). CAND, a specific, potent insurmountable inhibitor of AT 1 receptors (IC 50 Ͼ1ϫ10 Ϫ5 mol/L and 2.9ϫ10 Ϫ8 mol/L for AT 2 and AT 1 receptors, respectively), was used systemically for AT 1 receptor blockade in anesthetized animals. PD (Parke-Davis), a specific AT 2 receptor antagonist (IC 50 2ϫ10
Ϫ8 mol/L and Ͼ1ϫ10 Ϫ4 mol/L for AT 2 and AT 1 receptors, respectively), was used interstitially to block the AT 2 receptor. PC-18 (provided by Dr Bernard P. Roques), a specific APN inhibitor (K i ϭ8.0Ϯ1.7 nM), 20, 22 was infused interstitially to block the metabolism of Ang III to Ang IV.
Statistical Analysis
Comparisons among vehicle, AT 1 receptor blocker (CAND), AT 2 receptor blocker (PD), Ang III, and PC-18 (APN inhibitor) were estimated by ANOVA, including a repeated-measures term, by using the general linear models procedure of the Statistical Analysis System. Multiple comparisons of individual pairs of effect means were conducted by the use of least-square means pooled variance. Data are expressed as meanϮ1 SE. Statistical significance was identified at a level of PՅ0.05.
Results
As demonstrated in Figure 2 , in the presence of systemic CAND administration, RI Ang III infusion increased U Na V from a baseline of 0.05Ϯ0.01 to 0.07Ϯ0.01 mol/min (PϭNS) at 3. . o, U Na V responses to 4 cumulative RI Ang III infusions (3.5, 7, 14, and 28 nmol/kg per minute) after a 1-hour precontrol period during which only vehicle was infused. Ⅺ, U Na V when only 5% dextrose in water was infused into the RI space of the control kidney for the duration of the experiment. Data represent meanϮ1 SE; *PϽ0.05, **PϽ0.01, ***PϽ0.0001 from time control. 7 nmol/kg per minute, 6.21% versus 0.31% (PՅ0.01) at 14 nmol/kg/ per minute, and 14.7% versus 0.82% (PՅ0.01) at 28 nmol/kg per minute, respectively ( Figure 6 ). Thus, the addition of PD prevented the natriuretic response to RI Ang III plus PC-18 administration at each Ang III infusion rate.
MAP Responses to Intrarenal Ang III, Ang III Plus PC-18, and Ang III Plus PC-18 Plus PD Infusions in Rats on Normal Na
؉ Intake in the Presence of Systemic AT 1 
Receptor Blockade
As shown in Figure 7 , compared with time control during which only vehicle was infused, RI administration of Ang III, Ang III plus PC-18, or Ang III plus PC-18 plus PD did not result in a significant change in systemic MAP. Compared with Ang III-infused rats, MAP was significantly greater in Ang III plus PC-18 and Ang III plus PC-18 plus PD-infused animals, during both control and experimental periods (PϽ0.05 and PϽ0.01, respectively).
Discussion
The present studies demonstrate that RI Ang III, an AT 2 receptor ligand, induces a natriuretic response in the presence of systemic AT 1 receptor blockade. The natriuretic response was augmented by the intrarenal addition of PC-18 to Ang III and was blocked by the addition of PD, a specific AT 2 receptor antagonist. Because the metabolism of Ang III to Ang IV by APN is inhibited by PC-18, these data demonstrate that Ang III is a significant mediator of AT 2 receptor-induced natriuresis.
Ang III (Arg-Val-Tyr-Ile-His-Pro-Phe) is classically generated from the metabolism of Ang II (Asp-Arg-Val-Tyr-IleHis-Pro-Phe) by aminopeptidase A. In turn, APN metabolizes Ang III to Ang IV (Val-Tyr-Ile-His-Pro-Phe; Figure 1 ). Ang III is thought to possess biologic activity, both in renal and extrarenal tissues. In the brain, Ang III has been shown to cause vasoconstriction and mediate vasopressin release via the AT 1 receptor. 23, 24 In the adrenal gland, aldosterone production is stimulated by Ang III. 25 Ang III has also been reported to increase angiotensinogen levels and transforming growth factor-␤, fibronectin, and monocyte chemoattractant protein-1 gene expression in the kidney. 26, 27 Thus, whereas Ang II has traditionally been considered the major effector peptide of the systemic RAS, both Ang II and Ang III seem to exert biological activity in local tissue RAS.
Some authors argue that Ang III binds mainly to AT 2 receptors and exhibits a lower affinity for AT 1 receptors compared with that of Ang II. 28 In the myometrial cells of the pig uterus, the K i for Ang III at the AT 2 receptor is 2.2Ϯ0.2 nM, and in rat liver membranes, the K i for Ang III at the AT 1 receptor is 10.5Ϯ0.3 nM, corroborating this observation. However, in the brain, Ang II and Ang III have been noted to Figure 5 . U Na V responses to RI Ang III plus PC-18 plus PD compared with vehicle-infused kidneys in the presence of systemic AT 1 receptor blockade (Nϭ6). s, U Na V in response to 4 cumulative RI Ang III infusions (3.5, 7, 14, and 28 nmol/kg per minute) plus PC-18 (25 g/min) plus PD (10 g/min) after a 1-hour precontrol period during which only vehicle was infused. Ⅺ, U Na V when only vehicle was infused into the RI space of the control kidney for the duration of the experiment. Data represent meanϮ1 SE; *PϽ0.05 from time control kidney. display similar affinities for AT 1 and AT 2 receptors. 29, 30 The relative affinities for Ang II and Ang III for AT 1 and AT 2 receptors in the kidney have not been studied systematically. However, previous studies from our laboratory have demonstrated that RI infusion of Ang III, unlike Ang II, caused a significant natriuresis in the presence of systemic AT 1 receptor blockade. 17 The use of higher nanomolar concentrations of RI Ang II failed to induce a significant natriuretic response in that study. 17 The addition of PD (a specific AT 2 receptor antagonist) to intrarenal Ang III infusion abolished the Ang III-induced increase in natriuresis, providing pharmacological evidence that this effect is mediated by the AT 2 receptor. 17 Thus, it seems that within the intrarenal RAS, Ang III exerts a significant action at AT 2 receptors, at least in the presence of AT 1 receptor blockade.
In the systemic circulation, Ang III is metabolized 2 to 4 times faster than Ang II in both dogs and humans. 25, 31 APN is a major enzyme responsible for the metabolism of Ang III in the kidney. 23 APN is expressed on the brush border (apical) membranes of renal proximal tubule cells and enterocytes. 31 One of the first in vivo studies using PC-18 to inhibit the activity of APN was conducted in mice, 20 during which intracerebroventricular administration of PC-18 resulted in a 3.9-fold increase in the half-life of Ang III compared with control. The in vitro specificity of PC-18 toward APN, aminopeptidase A, and aminopeptidase B (APB), 3 zinc metalloproteases with significant identity between their amino acid sequences, was also tested in the study. 20 The K i values of this compound on APN were in the nanomolar range (K i ϭ8.0Ϯ1.7 nM), but PC-18 was 2150 and 125 times less active on aminopeptidase A and aminopeptidase B, respectively. 20 Thus, the infusion of PC-18 into the RI compartment in the present study allowed for examination of the effects mediated by Ang III within the intrarenal RAS, with the advantage of permitting the normally rapidly degraded peptide to remain available for a longer period of time. It should be mentioned, however, that PC-18 inhibition of APN, although quite specific, may have effects on other intrarenal peptides that are metabolized by APN (eg, kallidin). It is, therefore, possible that some of our results could be explained by increases in biologically active peptides metabolized by APN, other than Ang III. However, if this is the case, the effects of the other substrates of APN would also have to be mediated by the renal AT 2 receptor, given that the augmentation in natriuresis engendered by Ang III plus PC-18 was abolished by the coinfusion of PD, a specific AT 2 receptor antagonist.
Our data indicate that addition of RI PC-18 to Ang III infusion causes a 1.8-to 2.8-fold increase in Na ϩ excretion compared with RI Ang III infusion alone. Because the augmentation of the natriuretic response imparted by PC-18 was reduced by 73% to 95% with the coadministration of PD, the AT 2 receptor is largely responsible for this response. It should be noted, however, that PD infusion did not completely eliminate natriuresis in this study, suggesting that higher doses of the compound may be necessary for this effect or that other mechanisms resulting in continued natriuresis remain in play. Nonetheless, inhibition of the metabolism of Ang III by APN resulted in augmented natriuresis in AT 1 receptor-blocked rats, confirming our previous observations that Ang III is an important mediator of the natriuretic response in the kidney.
MAP was not altered by the RI infusion of Ang III, Ang III plus PC-18, or Ang III plus PC-18 plus PD in this study, indicating that the distribution of these peptides was almost certainly confined to the kidney during the experimental periods. Thus, systemic hemodynamic factors that might have played a role in the natriuresis were eliminated. It should be noted that MAP, during both control and experimental periods, was higher in the combined Ang III and PC-18 and Ang III, PC-18, and PD-infused animals compared with the animals infused with Ang III alone. Because the MAP before any RI infusion of pharmacological agents was higher in these groups, we interpret our data to mean that variability in baseline response to anesthesia between rats, rather than differences because of infused pharmacological agents, accounted for this effect.
In summary, the present studies demonstrate in AT 1 receptor-blocked rats that Ang III-induced natriuresis is augmented by infusion of PC-18, a compound that specifically inhibits APN, the enzyme primarily responsible for the Ang III degradation. The increase in natriuresis was blocked by the addition of a specific AT 2 receptor antagonist, PD, elucidating a role for the renal AT 2 receptor in natriuresis.
Perspectives
This study demonstrates that intrarenal pharmacological inhibition of the enzyme that metabolizes Ang III in the kidney (APN) results in an augmentation of Ang III-induced natriuresis mediated by the renal AT 2 receptor in the presence of systemic AT 1 receptor blockade. The regulation of APN at the renal level has not been studied systematically and remains open for future investigation. Additionally, the mechanisms by which Ang III induces AT 2 receptor-mediated natriuresis have yet to be elucidated. Our results suggest that APN and the AT 2 receptor are potentially important therapeutic targets in disorders characterized by Na ϩ and fluid retention, such as hypertension and congestive heart failure. Finally, because Ang II (and, thereby, its metabolites) is increased after chronic AT 1 receptor blocker therapy, some of the beneficial effects of this class of agents may be mediated by actions of Ang III at the AT 2 receptor.
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